匈牙利药品市场的未来:匈牙利监管机构的作用

M. Szentiványi
{"title":"匈牙利药品市场的未来:匈牙利监管机构的作用","authors":"M. Szentiványi","doi":"10.33892/aph.2021.91.131-132","DOIUrl":null,"url":null,"abstract":"The National Institute of Pharmacy and Nutrition (NIPN) has a long tradition as the safeguard of patient safety and as an institution that is committed to ensure that Hungarian patients have access to good quality, safe and efficacious medicines. During the last few years responsibilities of the Institute has been broaden and now we are also a key player in the regulation of special food and medical devices. During the past two decades a transition can be seen in the role of medicines agencies. While in the past the role of regulators was mainly acting as a gatekeeper, nowadays we also need to act as enablers. And while ensuring regulatory compliance of new medicines is still a key activity, our role cannot be narrowed down to the review of documents and other authorization tasks. This is due to the enormous development in the field of biotechnology, precision medicine, the revolution in synthetic biology, just to name a few. On one hand regulators need to be prepared for these new scientific challenges, on the other hand we have to be ready to give the necessary regulatory support to those developers that are coming from various fields and have limited knowledge and experience in regulatory issues.","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Future of the Hungarian Drug Market : Role of the Hungarian Regulatory Authority\",\"authors\":\"M. Szentiványi\",\"doi\":\"10.33892/aph.2021.91.131-132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The National Institute of Pharmacy and Nutrition (NIPN) has a long tradition as the safeguard of patient safety and as an institution that is committed to ensure that Hungarian patients have access to good quality, safe and efficacious medicines. During the last few years responsibilities of the Institute has been broaden and now we are also a key player in the regulation of special food and medical devices. During the past two decades a transition can be seen in the role of medicines agencies. While in the past the role of regulators was mainly acting as a gatekeeper, nowadays we also need to act as enablers. And while ensuring regulatory compliance of new medicines is still a key activity, our role cannot be narrowed down to the review of documents and other authorization tasks. This is due to the enormous development in the field of biotechnology, precision medicine, the revolution in synthetic biology, just to name a few. On one hand regulators need to be prepared for these new scientific challenges, on the other hand we have to be ready to give the necessary regulatory support to those developers that are coming from various fields and have limited knowledge and experience in regulatory issues.\",\"PeriodicalId\":6941,\"journal\":{\"name\":\"Acta pharmaceutica Hungarica\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta pharmaceutica Hungarica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33892/aph.2021.91.131-132\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta pharmaceutica Hungarica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33892/aph.2021.91.131-132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

国家药学和营养研究所(NIPN)作为患者安全保障和致力于确保匈牙利患者获得高质量、安全和有效药物的机构有着悠久的传统。在过去的几年里,研究所的职责已经扩大,现在我们也是特殊食品和医疗设备监管的关键参与者。在过去二十年中,可以看到药品机构的作用发生了转变。过去,监管机构的角色主要是看门人,而如今,我们也需要充当推动者。虽然确保新药的法规遵从性仍然是一项关键活动,但我们的作用不能缩小到审查文件和其他授权任务。这是由于生物技术领域的巨大发展,精准医学,合成生物学的革命,仅举几例。一方面,监管机构需要为这些新的科学挑战做好准备,另一方面,我们必须准备好为那些来自不同领域、在监管问题上知识和经验有限的开发商提供必要的监管支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Future of the Hungarian Drug Market : Role of the Hungarian Regulatory Authority
The National Institute of Pharmacy and Nutrition (NIPN) has a long tradition as the safeguard of patient safety and as an institution that is committed to ensure that Hungarian patients have access to good quality, safe and efficacious medicines. During the last few years responsibilities of the Institute has been broaden and now we are also a key player in the regulation of special food and medical devices. During the past two decades a transition can be seen in the role of medicines agencies. While in the past the role of regulators was mainly acting as a gatekeeper, nowadays we also need to act as enablers. And while ensuring regulatory compliance of new medicines is still a key activity, our role cannot be narrowed down to the review of documents and other authorization tasks. This is due to the enormous development in the field of biotechnology, precision medicine, the revolution in synthetic biology, just to name a few. On one hand regulators need to be prepared for these new scientific challenges, on the other hand we have to be ready to give the necessary regulatory support to those developers that are coming from various fields and have limited knowledge and experience in regulatory issues.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Insulin for topical use in wound healing: opportunities and limitations Rise and fall of fomivirsen, the first approved gene silencing medicine : A historical review Recent insight into strategies for the design of antimicrobial peptides (AMPs) Relative bioavailability study of a generic effervescent tablet formulation of dexketoprofen and thiocolchicoside versus the originator 25 mg film coated tablet (dexketoprofen) and 8 mg capsule (thiocolchicoside) Some Interactions of the Novel Photoswitchable Compound Phototrexate
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1